Member news

This week saw the publication of Engineering Biology Aspirations, the final output of Angela McLean’s Year of Engineering Biology. The report sets out an ambitious, forward-looking vision for the field, exploring how engineering biology could shape the future of everything from food and fashion to fuel and health.

Mosaic Therapeutics, Ltd, a targeted oncology therapeutics company dedicated to resolving cancer’s complexity with new combination therapies, announced the in-licensing of two clinical-stage oncology programs.

Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have entered into a research collaboration and global license agreement.

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapy products for the treatment of multiple cancers, announces a partnership with the NHS Cancer Vaccine Launch Pad (CVLP) to fast-track access for NHS patients into the fourth cohort of the Company’s Phase 2 clinical SCOPE study. 

Myricx Bio (‘Myricx’ is pleased to announce team expansion, with the appointment of Steen Lisby, M.D., D.MSc. as CMO and Jesper Valbjørn, M.Sc. as SVP CMC.

eXmoor Pharma, a full-service Cell and Gene Therapy (CGT) CDMO, has appointed Dr James Miskin as Non-Executive Director.

The agreement is expected to serve as a critical foundation for activating international joint research, academic exchange and research collaboration in quantum fields, including quantum computing.

Coulter Partners successfully completed a search assignment for iOnctura and is pleased to announce the placement of Dr. Mark Velleca as Chair of the Board of Directors.

The workshop brought together leading academic researchers, industry experts and innovators to explore the fundamentals of AlphaFold – an artificial intelligence (AI) program developed by Google DeepMind to predict the 3D structure of proteins.

Brainomix 360 unlocks expert-level insights from universally available non-contrast CT scans, helping stroke networks expand access to life-changing treatments.

ELRIG, a not-for-profit, volunteer-led organisation dedicated to the drug discovery community, has appointed Dr Del Trezise as Chair of the Board.

Cancer Research Horizons has announced a collaboration with Histofy to develop tools that predict how colorectal cancer patients respond to different treatment options using the multi-modal S:CORT dataset.

Judges lauded the cutting-edge CRO, RSSL, for its exceptional service to over 3,000 clients in 60+ countries, alongside its continued investment in services, technology and team.

Coulter Partners successfully completed a search assignment for Altimmune Inc. (Nasdaq: ALT), and is pleased to announce the placement of biopharmaceutical industry executives Teri Lawver and Jerry Durso to its Board of Directors.

Multiomic Health and Alloy Therapeutics, Inc. have today announced a collaboration to discover and develop renal tissue-targeting drugs. The collaboration provides external validation of MultiOmic Health’s AI-enabled precision medicine discovery platform and innovative renal therapeutic programs.

Miltenyi Biotec, an innovator of products and services for biomedical research and cell and gene therapies, has announced a strategic partnership with leading developer of life science ecosystems, integrating infrastructure, investment, and venture support, Pioneer Group.

Discovery Park has successfully concluded its latest Discovery Spark programme, an intensive business growth catalyst supporting early-stage start-ups.

It's #CDMOWeek here at VectorBuilder! 🧬 And we're spotlighting innovations that are shaping the future of cell and gene therapy manufacturing.

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, is delighted to announce the strengthening of its management team with the promotion of Penny Sadler as Managing Partner.

Isomorphic Labs will utilise the funding to further power its AI drug design engine through frontier AI research and development and to scale and progress its drug candidate pipeline.